GlassScriptPhysician profile
Astrid C Marshall
NPI 1457884108
$1,630.34
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.81 · 2021: $209 · 2022: $1,023 · 2023: $323 · 2024: $58.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $815.78 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $124.78 | 2023-2024 | Myfembree |
| Abbvie INC. | $110.81 | 2021-2023 | |
| Organon LLC | $101.97 | 2021-2023 | Nexplanon |
| Agile Therapeutics, INC. | $101.87 | 2021-2023 | Twirla |
| Avion Pharmaceuticals | $87.69 | 2021-2023 | Balcoltra |
| Myovant Sciences INC. | $41.41 | 2022 | |
| Aspira Women'S Health INC | $40.34 | 2022 | |
| Mayne Pharma Commercial LLC | $38.86 | 2022 | |
| Coopersurgical, INC. | $34.79 | 2021-2024 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $25.83 | 2022 | |
| Convatec INC. | $21.11 | 2023 | |
| Evofem Biosciences, INC. | $20.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2024 | |
| Boston Scientific Corporation | $15.81 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $14.28 | 2023 | Slynd |
| Therapeuticsmd, INC. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Astrid Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.